Cargando…

Outcome of repeat dosing of sJIA patients with tocilizumab in one UK centre

Detalles Bibliográficos
Autores principales:	Livermore, P, Woodworth, T, Woo, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334045/ http://dx.doi.org/10.1186/1546-0096-6-S1-P24

Ejemplares similares

IL-18 production upon s100 stimulation is reduced in active sJIA patients compared to sJIA patients in remission and healthy controls
por: Haar, Nienke Ter, et al.
Publicado: (2014)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
por: De Benedetti, F, et al.
Publicado: (2011)

Tocilizumab for the treatment of systemic onset JIA: a single centre experience from India
por: Sawhney, Sujata, et al.
Publicado: (2012)

PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
por: Lu, P, et al.
Publicado: (2013)

The efficacy and safety of Tocilizumab in adults with refractory systemic onset JIA
por: Deslypere, G, et al.
Publicado: (2011)

Mitochondrial and oxidative stress genes are differentially expressed in neutrophils of sJIA patients treated with tocilizumab: a pilot microarray study
por: Omoyinmi, Ebun, et al.
Publicado: (2016)

PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)
por: De Benedetti, F, et al.
Publicado: (2013)

An in-depth analysis of young people's experience of their juvenile idiopathic arthritis (JIA) once receiving Etanercept
por: Livermore, P, et al.
Publicado: (2008)

Mutations of familial hemophagocytic lymphohistiocytosis (FHL) related genes and abnormalities of cytotoxicity function tests in patients with macrophage activation syndrome (MAS) occurring in systemic juvenile idiopathic arthritis (sJIA)
por: Bracaglia, Claudia, et al.
Publicado: (2014)

PReS-FINAL-2038: Clinical efficacy and tolerability of tocilizumab in patients with persistant systemic JIA
por: Mihailova, D, et al.
Publicado: (2013)

Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data
por: Ruperto, N, et al.
Publicado: (2014)

S100A12 as diagnostic tool in the differential diagnosis of sJIA associated MAS vs. hereditary or acquired HLH
por: Holzinger, D, et al.
Publicado: (2015)

Tocilizumab in JIA patients who have inadequate response to anti-tumour necrosis factor therapy
por: Russo, R, et al.
Publicado: (2011)

PReS-FINAL-2139: Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study
por: De Benedetti, F, et al.
Publicado: (2013)

PReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial
por: Malattia, C, et al.
Publicado: (2013)

Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)
por: Kumar, Sharath, et al.
Publicado: (2012)

An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)
por: Bullement, Ash, et al.
Publicado: (2021)

Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset
por: Ravelli, A, et al.
Publicado: (2014)

Tocilizumab (TCZ) may be an effective treatment for poly-juvenile idiopathic arthritis (pJIA) as for rheumatoid arthritis (RA)
por: Yamaguchi, Ken-ichi, et al.
Publicado: (2012)

Experience of one UK site presenting a closer examination of safety and efficacy of Anakinra (Kineret(®)) in systemic juvenile idiopathic arthritis
por: Livermore, P, et al.
Publicado: (2008)

Genes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease
por: Brachat, A, et al.
Publicado: (2015)

Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA – an analysis of 12-week pooled data
por: Ravelli, A, et al.
Publicado: (2014)

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
por: Ruperto, N, et al.
Publicado: (2008)

PReS-FINAL-2040: Outcome of macrophage activation syndrom (MAS) in systemic juvenile idiopatic arthritis (SJIA) in non biologic treated patient
por: Lazarevic, DS, et al.
Publicado: (2013)

Juvenile idiopathic arthritis (JIA) in two tertiary centres in the Western Cape, South Africa
por: Weakley, Kate, et al.
Publicado: (2011)

PReS-FINAL-2188: Insulin sensitivity is improved in sjia children with insulin resistance after tocilizumab treatment: results from the tender study
por: Mirjafari, H, et al.
Publicado: (2013)

Are genetic variants of Caspase-1 and Cryopyrin associated with systemic JIA?
por: Stock, CJ, et al.
Publicado: (2008)

PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy
por: Nirmala, N, et al.
Publicado: (2013)

MEFV mutations in systemic JIA
por: Aktay Ayaz, N, et al.
Publicado: (2008)

Mesenchymal stem cells and JIA
por: Swart, JF, et al.
Publicado: (2011)

The swedish paediatric JIA-registry
por: Magnusson, Bo
Publicado: (2014)

Puberty and disease activity in JIA
por: Van Pelt, Philomine, et al.
Publicado: (2014)

Clinical classification of JIA in Albania
por: Vula, Aurel, et al.
Publicado: (2014)

Efficacy of canakinumab in biologic-naïve versus previously biologic-exposed SJIA patients: a 12 week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2014)

Abatacept for severe anti-TNF-alfa refractory JIA-associated uveitis: one year follow-up
por: Alpigiani, MG, et al.
Publicado: (2011)

Understanding the biology and use of TNF therapy in jia-clinical outcomes
por: Lovell, Daniel, et al.
Publicado: (2014)

Pregnancy outcomes in women affected by juvenile idiopathic arthritis (JIA)
por: Alpigiani, Maria Giannina, et al.
Publicado: (2014)

PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients
por: Quartier, P, et al.
Publicado: (2013)

Ocular threat in juvenile idiopathic arthritis (JIA)
por: Marvillet, I, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_2r1rg558p2cc1dfjndii46vk3a